UK set to ban THCA and HHC cannabinoids
United Kingdom plans to restrict two synthetic and hemp-derived cannabinoids as regulatory focus tightens on non-intoxicating compounds.
FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0The United Kingdom is moving to ban THCA and HHC cannabinoids, according to reporting from Newsweed. The move represents a tightening of UK cannabis regulation beyond CBD, which the Food Standards Agency recommended approving as a novel food in September 2026, and signals potential friction between medical-access frameworks and consumer-market cannabinoid products.
The timing suggests regulatory pressure on compounds marketed outside traditional pharmaceutical channels. Recent UK expansion by licensed operators—including Tilray's production scale-up to 275 metric tons annually, Curaleaf Labs' manufacturing partnership, and Canopy Growth's medical supply entry—has coincided with stricter designation of unregulated derivatives. A U.S. brand like Airo's October launch of an inhalation system in the UK may face tighter product-approval pathways if THCA and HHC restrictions broaden.
Watch for clarification on enforcement timelines and whether the ban extends to imports or only domestic sales, particularly given the number of recent licensing and distribution deals signed by established operators seeking to anchor the UK medical and licensed retail space.
Original report: Newsweed ↗